Abstract: The present invention concerns gp36 immunoreactive compositions for E. canis and gp 47 immunoreactive compositions for E. chaffeensis. In particular, epitopes for E. canis gp36 and E. chaffeensis gp 47 are disclosed. In certain embodiments, the immunoreactive compositions comprise tandem repeats having carbohydrate moieties.
Abstract: The present invention relates to methods for treating and preventing Staphylococcus aureus infection and/or a condition resulting from a S. aureus infection in a subject that involves administering compositions that inhibit S. aureus interaction with CXCR1/CXCR2 and DARC cellular receptors. The present invention further relates to novel compositions for carrying out these and other methods.
Type:
Grant
Filed:
June 5, 2020
Date of Patent:
September 27, 2022
Assignee:
NEW YORK UNIVERSITY
Inventors:
Victor J. Torres, Tamara Reyes-Robles, Francis Alonzo, III
Abstract: Methods are provided for the synthesis and secretion of recombinant hetero-multimeric proteins in mating competent yeast. A first expression vector is transformed into a first haploid cell; and a second expression vector is transformed into a second haploid cell. The transformed haploid cells, each individually synthesizing a non-identical polypeptide, are identified and then genetically crossed or fused. The resulting diploid strains are utilized to produce and secrete fully assembled and biologically functional hetero-multimeric protein.
Type:
Grant
Filed:
March 11, 2019
Date of Patent:
September 20, 2022
Assignees:
KECK GRADUATE INSTITUTE, H. LUNDBECK A/S
Inventors:
James M. Cregg, John A. Latham, Mark Litton, Randall Schatzman, Ilya I. Tolstrorukov
Abstract: The invention relates to a recombinant Mycobacterium cell for use as an immunotherapeutic agent in the treatment of cancer, particularly in the treatment of solid tumors. More particularly, the invention relates to the immunotherapy of bladder carcinoma.
Abstract: The invention provides a composition comprising a bacterial strain of the genus Megasphaera, for use in stimulating the immune system in subject.
Type:
Grant
Filed:
September 4, 2020
Date of Patent:
August 23, 2022
Assignee:
4D Pharma Research Limited
Inventors:
Imke Elisabeth Mulder, Parthena Fotiadou, Amy Beth Holt, Suaad Ahmed, Anna Ettorre, Samantha Yuille, Ted Dinan, John Cryan
Abstract: The invention relates to plasmids capable of expressing a protein targeting immune cells when transformed into a lactic acid bacterial cell, wherein the protein is chosen from the group consisting of murine and human CXCL12 1?; CXCL17 and Ym1. The invention further relates to lactic acid bacteria transformed with a said plasmid, as well as the use of said lactic acid bacteria for wound healing in humans and animals.
Abstract: There is provided novel peptides for use in diagnosis of CagA+ H. pylori infection or the prediction of risk for gastric cancer. The peptides bind antibodies from CagA+ H. pylori patients with high specificity and sensitivity, and can be used for example in a diagnostic kit.
Abstract: The present invention relates to aptamers, polynucleotides, and nucleic acid molecules, which include a polynucleotide sequence capable of specifically binding polypeptides participating in M. hyopneumoniae infection. Also provided are methods of using nucleic acid molecules, polynucleotides and synthetic antibodies directed there against for detection, treating and neutralization of M. hyopneumoniae infection.
Type:
Grant
Filed:
August 30, 2017
Date of Patent:
July 26, 2022
Inventors:
Norman J Marchand, Thomas G Caltagirone, Albert Liao
Abstract: The present disclosure provides molecules which modulate cell growth. These molecules include those that bind sialic acid which may find application in the treatment and/or prevention of cell proliferation and/or differentiation disorders, cancer and/or it's migration and/or spread.
Type:
Grant
Filed:
September 20, 2017
Date of Patent:
July 19, 2022
Assignee:
OMIDEON LIMITED
Inventors:
Helen Connaris, Judith Telford, Graeme Rogers
Abstract: The disclosure discloses a probiotic mixed preparation with anti-influenza ability and application thereof, and belongs to the technical fields of microorganisms and medicines. The probiotic mixed preparation has anti-influenza effects, which are embodied in: (1) significantly reducing the degree of weight loss of influenza mice; (2) significantly improving the blood indexes of the influenza mice; (3) significantly improving the inflammation status of respiratory tract infections in the influenza mice; (4) significantly reducing the viral load in the lungs of the influenza mice (i.e., significantly inhibiting the replication and multiplication of influenza viruses in the influenza mice); and (5) significantly increasing the expression quantity of antiviral protein MxA in the lungs of the influenza mice. Therefore, the probiotic mixed preparation has great application prospects in preparation of a product for preventing and/or treating atopic dermatitis and even preventing and/or treating influenza.
Abstract: The invention relates to Plasmodium antigenic polypeptides identified through the use of a specifically devised functional immunization screening assay. In particular, the invention relates to antigenic polypeptides of malaria parasites wherein said antigenic polypeptides that exhibit a protective effect, especially that of eliciting a protective immune response in a host against challenge by Plasmodium sporozoites. The invention relates to a combination of compounds, comprising at least 2 distinct active ingredients wherein each active ingredient consists of an antigenic polypeptide of a Plasmodium parasite, a polynucleotide encoding the antigenic polypeptide, or a vector, in particular a viral vector, especially a lentiviral vector, expressing such antigenic polypeptide of a Plasmodium parasite, wherein one antigenic polypeptide is the circumsporozoite protein (CSP) or a polypeptidic derivative thereof and another antigenic polypeptide is either protein Ag40 (11-09) or protein Ag45 (11-10).
Type:
Grant
Filed:
February 1, 2018
Date of Patent:
June 28, 2022
Assignees:
Institut Pasteur, Centre National de la Recherche Scientifique
Inventors:
Rogerio Amino, Pierre Charneau, Anne-Sophie Beignon, Catherine Blanc
Abstract: The present disclosure relates to methods and compositions for treating a active tuberculosis infection and methods and compositions for improving the efficacy of chemotherapy regimens against active tuberculosis infection. The present disclosure relates to methods of treating an active M. tuberculosis infection or an active infection resulting from reactivation of a latent infection in a mammal and to methods of improving the efficacy of chemotherapy regimens against active M. tuberculosis infection.
Abstract: The present invention relates to Shiga toxin A Subunit derived polypeptides and cell-targeting molecules comprising amino acid substitutions which equip the polypeptides with 1) de-immunization; 2) reduced, protease-cleavage sensitivity; and/or 3) a heterologous epitope cargo(s) while retaining Shiga toxin function(s), such as, e.g., potent cytotoxicity. Certain polypeptides of the invention exhibit reduced immunogenic potential in mammals and/or are capable of delivering an epitope to an MHC class molecule of a cell in which the polypeptide is present. Certain molecules comprising a polypeptide of the invention are well-tolerated by mammals while retaining one or more of the features mentioned above.
Type:
Grant
Filed:
April 19, 2021
Date of Patent:
June 21, 2022
Assignee:
Molecular Templates, Inc.
Inventors:
Eric Poma, Erin Willert, Garrett Lee Robinson, Sangeetha Rajagopalan, Brigitte Brieschke
Abstract: Combination therapeutics for the treatment of cancer include the use of immune effector cells, IL-15 based superagonists and one or more immunotherapeutic agents such as Bacillus Calmette-Guerin (BCG).
Abstract: Herein is reported a method for determining bacterial endotoxin at low concentrations in a sample of an antibody (that has been produced using bacterial cells) comprising the following steps in the following order: i) adding magnesium ions to the sample, ii) diluting the sample, iii) dialyzing the sample having a pH-value of 5.7-8.0 against an endotoxin-flee aqueous solution, and iv) determining bacterial endotoxin in the sample using a bacterial endotoxin test, particularly the Limulus amoebocyte lysate assay.
Type:
Grant
Filed:
January 28, 2020
Date of Patent:
June 14, 2022
Assignees:
Forschungszentrum Borstel Leibniz Lungenzentrum, Hoffmann-La Roche Inc.
Inventors:
Christian Alexander, Sven Deutschmann, Pierre Lang, Friedrich Von Wintzingerode, Ulrich Zaehringer
Abstract: The present invention relates to animal feed or animal feed additive comprising Bacillus strains which improve the health and performance of production animals. The invention further relates use of the Bacillus strains in animal feed and animal feed additives.
Abstract: The invention relates to multiple epitope constructs, immunogenic and vaccine compositions comprising recombinant molecules presenting inserted multiple and different epitopes from a variety of antigens. The antigenic determinants being associated with different pathways leading to atherosclerosis. In particular, the invention relates to such compositions for eliciting an immune response against antigens and pathogens involved in the development of atherosclerosis the invention includes inter alia methods of treating and/or preventing the disease and recombinant protein products.
Abstract: The present invention can be included in the field of diagnostics. The present invention provides hybridomas, antibodies and test devices for the detection of bacteria of the genus Campylobacterin a sample. Further, the present invention discloses the uses of the antibodies and a method for detecting bacteria of the genus Campylobacter. The antibodies of the present invention are specific for DNA-Binding Protein from Starved Cells (Dps) and provide less false positives and a higher sensitivity when used in an immunochromatographic test device than other antibodies used to detect bacteria of the genus Campylobacter.
Type:
Grant
Filed:
October 2, 2018
Date of Patent:
April 26, 2022
Assignee:
CERTEST BIOTEC, S.L.
Inventors:
Oscar Landeta Elorz, Yolanda García Miguel, Juan Enrique Martínez Oliván, Beatriz Velasco Michelena
Abstract: In various embodiments devices and methods for the detection and/or quantification of clinically relevant pathogens (e.g., bacteria, fungi, viruses, etc.) are provided. In certain embodiments the device comprises a lateral-flow assay that detects the bacterium at a concentration of less than about 6×106 cells/mL, less than about 3×106 cells/ml, less than about 1×106 CFU/mL, or less than about 50 ?g/mL. In certain embodiments the device comprises an aqueous two-phase system (ATPS) comprising a mixed phase solution that separates into a first phase solution and a second phase solution; and a lateral-flow assay (LFA). In certain embodiments the device comprises a flow-through system comprising a concentration component comprising an aqueous two-phase system (ATPS) comprising a mixed phase solution that separates into a first phase solution and a second phase solution; and a detection component disposed beneath said concentration component.
Type:
Grant
Filed:
September 2, 2016
Date of Patent:
March 29, 2022
Assignee:
The Regents of the University of California
Inventors:
Daniel T. Kamei, Yin To Chiu, Benjamin M. Wu, Garrett L. Mosley